

# TAIWAN

Your Best Partner in Asia

Your Best Partner in Asia



Delegation Website



BPIPO Website

## Taiwan Pavilion

Booth No. 1917 & 1817

### One-Stop-Shop for Taiwan Biomedical Industry

**BPIPO** Biotechnology and Pharmaceutical Industries Promotion Office, MOEA

Tel: +886 (2) 2655 8135

Email: [services@biopharm.org.tw](mailto:services@biopharm.org.tw)

Web: [www.biopharm.org.tw](http://www.biopharm.org.tw)

2024 BIO International Convention  
June 3-6, 2024

## Taiwan, Your Best Partner in Asia!

As the center of Asia-Pacific region, Taiwan is not only a crucial link between Europe, America, Japan and the emerging Asia-Pacific markets, but also a preferred location for multinational companies to establish their regional headquarters.

In addition, Taiwan's government actively promotes the precision health industry to realize interdisciplinary collaboration to reach the goal, a vision of whole-life health, in 2030.



## Comprehensive Bio-Clusters

### Northern


- Drugs (Discovery, Biologics, Pharmaceuticals)
- Medical Devices (Diagnostics, Medical Electronics, IVD, Medical Imaging)

### Central

- Drugs (Pharmaceuticals, Vaccines)
- Medical Devices (Rehabilitation Devices, Minimal Invasive Surgical Devices)

### Southern

- Drugs (API)
- Medical Devices (Implantable Devices, Minimal Invasive Surgical Devices)
- Herbal Medicines, Functional Foods, Animal Breeding and Vaccines





**1st** | Health Care Index (Numbeo 2024)

**4th** | Economic Freedom Index (Heritage Foundation 2024)

**6th** | World Competitiveness (IMD 2023)

**9th** | Digital Competitiveness (IMD 2023)


## Exhibit Hall Floor Plan



## Exhibit Hall Floor Plan


Please refer to the content pages for information on delegates booth points and introductions.

### Booth No. 1917



+: info. desk

### Booth No. 1817



## Content

<b>Biologics</b>	No.	Page
ACRO Biomedical Co., Ltd.	06	01
BIONET Corp	22	02
CytoArm Co., Ltd.	27	03
LumiSTAR Biotechnology, Inc.	28	04
MycoMagic Biotechnology	16	05
OBI Pharma, Inc.	03	06
PharmaEssentia Corp.	15	07
PrecisemAb Biotech Co., Ltd.	32	08
Taiwan Universe BioMedicine	27	09

<b>Biotech (incl. Agriculture)</b>	No.	Page
AcroCyte Therapeutics	28	10
CancerFree Biotech	29	11
Elixiron Immunotherapeutics	05	12
Everfront Biotech Inc.	18	13
Health Ever Bio-Tech Co., Ltd.	04	14
Hughes Biotechnology Co., Ltd.	22	15
Oneness Biotech Co., Ltd.	23	16
Pythia Biotech Ltd.	20	17
Simpson Biotech Co., Ltd.	02	18
Suntec Medical Inc.	26	19
TLC BioSciences	17	20

<b>Biotech (incl. Agriculture)</b>	No.	Page
Trust Bio-sonics Inc.	20	21
Xantho Biotechnology Co., Ltd.	07	22

<b>CDMO</b>	No.	Page
Bora Biologics Co.,Ltd.	01	23
KriSan Biotech	08	24

<b>Medical Device</b>	No.	Page
AHEAD Medicine Corp.	25	25
BioPro Scientific	24	26
DotSPACE Inc.	19	27
iPreg Inc.	32	28
Lixel Inc.	07	29
Moleculex Co., Ltd.	31	30
Origin Biotechnology Co.,Ltd.	21	31
QT Medical, Inc.	21	32

<b>Precision Health</b>	No.	Page
Anivance AI	25	33
CytoAurora Biotechnologies	24	34
JelloX Biotech Inc.	30	35

## Content

<b>Precision Health</b>	No.	Page
Marker Exploration Corporation	31	36

<b>Small Molecule Drug</b>	No.	Page
Anbogen Therapeutics	29	37
ImmunAdd Inc.	26	38
Neural Rejuvenation, Team Biomedical Translation Research Center Academia Sinica	09	39
Sinew Pharma Inc.	09	40
TAHO Pharmaceuticals Ltd.	23	41

<b>Smart Health</b>	No.	Page
FaceHeart Corp.	19	42
Neurobit Technologies Co., Ltd.	30	43

<b>Government/Non-Profit Institution</b>	No.	Page
Agricultural Technology Research Institute	-	44
Biomedical Translation Research Center Academia Sinica	10	45
Central Taiwan Science Park	-	46
China Productivity Center	-	47
Department of Academia-Industry Collaboration and Science Park Affairs, National Science and Technology Council	-	48

<b>Government/Non-Profit Institution</b>	No.	Page
Development Center for Biotechnology	12	49
Hsinchu Science Park Bureau, National Science and Technology Council	-	50
Industrial Development Administration, Ministry of Economic Affairs	-	51
Industrial Technology Research Institute	11	52
Medical and Pharmaceutical Industry Technology and Development Center	13	53
Ministry of Agriculture	-	54
Ministry of Health and Welfare of the Republic of China	-	55
National Health Research Institutes	14	56
National Science and Technology Council	-	57
Southern Taiwan Science Park Bureau, National Science and Technology Council	-	58
Startup Island TAIWAN	-	59
Taipei City Government	-	60
Taipei Exchange	-	61
Taiwan Bio Industry Organization	08	62
Taiwan External Trade Development Council	-	63
Taiwan Stock Exchange	-	64



### Business Interests

- Distribution
- ODM/OEM
- R&D Collaboration
- Licensing

### ACRO Biomedical Co., Ltd.

#### Main Products / Services / Pipelines & Platforms

- ABCcolla® Collagen Matrix - The porous collagen biomaterial absorbs wound exudates and maintains a moist environment conducive to healing.
- ABCcolla® Bone Graft - It is intended for filling and augmentation of bone voids or gaps during orthopedic and dental surgeries. It facilitates cell attachment and improves bone regeneration and neovascularization.
- ABCcolla® Collagen Ophthalmic Matrix - It is intended for cornea transplantation in replacement of human donated cornea.
- ACROTERM™ Tissue & Organ Scaffolds - Native collagen scaffolds derived from porcine tissues and organs, decellularized by supercritical CO<sub>2</sub> extraction technology. All scaffolds retain their native ECM structures and are biocompatible for stem cell culture and tissue engineering research.
- ACROTERM™ Tissue & Organ Scaffold Powders - Native collagen scaffold powders derived from porcine tissues and organs, decellularized by supercritical CO<sub>2</sub> extraction technology. All scaffold particles retain their native ECM structures, suitable for 3D bioprinting research purposes.

### Contact Information

Name  
**Ni Wang**  
Position  
**Marketing Specialist**  
Tel  
**+886 (7) 695 5569 Ext.228**  
Email  
**niwang@acrobiomedical.com**



### Business Interests

CRDMO opportunities for regenerative medicine techniques, bioinformatic service, and precise medicine development with biomedicine companies.

### BIONET Corp.

#### Main Services

- **Exosome Development**
  1. Skin Regeneration
  2. Hair Restoration
  3. Reduce Inflammation
  4. Customized CRDMO Products
- **CRDMO Service**
  1. Cell Preparation
  2. Cryopreservation Service
  3. Bioinformatic Analysis
  4. Exosome CRDMO Services
- **Cell Therapy**
  1. Hematopoietic Stem Cells
  2. Mesenchymal Stem Cells
  3. Immune Cells
- **Scientific Informatics**
  1. Bioinformatics
  2. Multiscale Modeling
  3. Smart Manufacturing

### Contact Information

Name  
**Amelia Yang**  
Position  
**Sales Supervisor**  
Tel  
**+886 (2) 2795 1777 Ext.1517**  
Email  
**AmeliaYang@GGA.ASIA**



### Business Interests

- Out-Licensing of Armed-T cell Technology and Products
- Clinical Trial Collaboration
- Fundraising

### CytoArm Co., Ltd.

#### Main Products / Services / Pipelines & Platforms

##### Main Product of Armed-T Cell Technology

- The lead Armed-T cell product, CTA-002, is for treating colorectal cancer (CRC) with EGFR downstream (Kras, Braf, and Nras) mutations (present in approximately 50% of untreatable CRC patients).
- Preclinical data have shown that CTA-002 is highly tumor-specific and effective in reducing the tumor burden of CRC tumors. No signs of cytokine release syndrome and other toxicities were observed.
- CTA-002 is ready to initiate clinical trials for untreatable CRC in the US, Singapore, and Taiwan in 2024.

##### Pipelines of Other Armed-T cell products

- CTA-001 for B-cell leukemia and CTA-006 for recurrent/refractory solid tumors have been sublicensed to expedite their entry into clinical trials in 2024.
- CTA-003 for prostate tumor and CTA-004 for metastatic breast tumor are under development in the CMC stage.
- Over 50 products are protected by worldwide patents.

### Contact Information

Name  
**Ting-Yu (Michael) Chen**  
Position  
**VP**  
Tel  
**+886 930 659 571**  
Email  
**tingyu.chen@cytoarm.com**



### Business Interests

- Out-Licensing
- Collaborative R&D for Drug Discovery
- Clinical Collaboration on iPSC-based Cell Therapies

### LumiSTAR Biotechnology, Inc.

#### Main Products / Services / Pipelines & Platforms

iPSC technology and live cell imaging platform- A platform monitoring cellular characteristics as indicators of drug efficacy or cellular functionality for high throughput/content screening.

#### Applications

##### Our Drug Discovery Pipelines:

- Neurodegenerative Diseases (Alzheimer's and Parkinson's)
- Anti-fibrosis
- Anti-viral agents

##### Our iPSC Cell Therapy Pipelines:

- Parkinson's Disease
- Renal Fibrosis
- Solid Tumors (iPSC-NK)

### Contact Information

Name  
**Chih-Chuan Su**  
Position  
**Senior Business Development Manager**  
Tel  
**+886 978 908 181**  
Email  
**chih-chuan.su@lumistar.com.tw**



## Business Interests

- Out-Licensing
- Collaborative Product Development
- Academic/ Industry Research Partner

## MycoMagic Biotechnology

### Main Products / Services / Pipelines & Platforms

MycoMagic Biotech, founded in 2005, is a leader in the identification, functional verification, and large-scale manufacturing of novel bioactive proteins derived from edible mushrooms with health advantages. Our focus is to use nature to develop innovative functional proteins for healthcare and wellness.

### Main Product

**Ganoderma microsporum Immunomodulatory Protein (GMI) : A Revolution in Regenerative Healthcare**

Ganoderma microsporum-derived GMI is an innovative recombinant protein produced using cutting-edge yeast biotechnology. It is a key to achieving the complete potential of regenerative therapies; it is more than just a protein.

### Product Features

**High-Quality Production:** Produced with precision biotechnology to ensure consistency and quality.

**Stem Cell Growth:** Enhance stem cell proliferation, paving the way for breakthrough regenerative treatments.

**Immunity Boosting:** Strengthens the immune system, enhancing overall health and helping fight cancer.

**Versatile Use:** A safe and crucial ingredient for the future of regenerative healthcare and therapy products.

GMI is transforming healthcare possibilities, offering new hope for regenerative medicine.

## Contact Information

Name  
**Manen Fong**  
Position  
**International Project Manager**  
Tel  
**+886 (2) 2662 0148 Ext.227**  
Email  
**manenfong@mycomagic.com.tw**



## Business Interests

- ADC platform technologies - OBI is looking for collaborative R&D and out-license opportunities to create first- or best-in-class ADCs.
- OBI's novel cancer therapeutics - OBI is seeking out-licensing opportunities to expedite the clinical development of our pipeline products.

## OBI Pharma, Inc.

### Main Products / Services / Pipelines & Platforms

OBI Pharma, Inc., is a Taiwan biopharmaceutical company publicly-listed on the Taipei Exchange (TPex ticker: 4174). OBI's mission is to develop and license novel therapeutic agents for unmet medical needs of cancer patients. OBI holds proprietary ADC platform technologies and has a novel oncology portfolio:

### ADC platform technologies

- GlycOBI™
- ThiOBI™

### Novel cancer therapeutics

- Adagloxad Simolenin (formerly OBI-822; Globo H cancer vaccine)
- OBI-833 (Globo H cancer vaccine)
- OBI-3424 (small-molecule prodrug targeting AKR1C3 enzyme)
- OBI-992 (TROP2 ADC, Cys-conjugation platform)
- OBI-902 (TROP2 ADC, GlycOBI platform)
- OBI-904 (Nectin4 ADC, GlycOBI platform)
- OBI-905 (HER2 ADC, GlycOBI platform)

## Contact Information

Name  
**Kevin Poulos**  
Position  
**Chief Business Officer**  
Tel  
**+619 537 7698 Ext.102**  
Email  
**kpoulos@obipharmausa.com**





## PharmaEssentia Corp.

### Business Interests

- Licensing

### Main Product

Besremi (ropeginterferon alfa-2b)

### Contact Information

Name  
**Derek Yuan**  
Position  
**Business Development Director**  
Email  
**derek\_yuan@pharmaessentia.com**



## PrecisemAb Biotech Co., Ltd.

### Business Interests

- Cooperation Partners of Lead Product-PSM101
- Strategic Partners of ADC
- Customized Antibody Lock Design Service
- Out-Licensing of Lock-Antibodies

### Contact Information

Name  
**Yun-Chi Lu**  
Position  
**President & Co-Founder**  
Tel  
**+886 (7) 7311 1577**  
Email  
**yunchi.lu@precisemab.com**

### Main Services / Platforms

Antibody drugs lead to serious side effects because they cannot distinguish disease tissue from normal tissue. Universal Antibody Lock allows antibody drugs, including ADC and bispecific antibodies, to take effect only in diseased areas, solving systemic toxicity and making antibody treatment safe and effective. Now, we are developing the first-in-class antibody drug, PSM101, for advanced head and neck cancer.

### Features

- Medication safety with minimized adverse effects
- Elevating treatment efficacy for cancer cure
- Precision-designed for targeting various cancers

### Partnering

**PrecisemAb licenses Lock-antibodies for further clinical trials through:**

- **Co-development of Lock-antibodies**

[Oncology] Lock-EGFR, Lock-PD1, Lock-CTLA4, Lock-4-1BB  
[Autoimmune disease] Lock-TNF  $\alpha$ , Lock-IL-1 $\beta$

- **Customized Antibody Lock Design Service**

Including 4 steps to design your own Lock-antibody.

## Taiwan Universe BioMedicine

---

### Business Interests

- Out-Licensing
- Collaborative R&D

### Main Product

Innovative platform of enterovirus and influenza VLP vaccines.

- Promising option to combat viruses mutation
- Provide a broad-spectrum prevention with better immunogenicity
- Enable faster scaling-up

### Contact Information

Name  
**Claire Chiu**  
Position  
**COO**  
Tel  
**+886 932 796 340**  
Email  
**cchiu@nhri.edu.tw**



## AcroCyte Therapeutics

---

### Business Interests

- Looking for distributors for 3D culture market
- Targeting B2B or B2C clients who are interested in organoid/3D culture

### Main Products

#### R3CE™ (Rapid, Reproducible, Rare Cell Expansion) platform

- 3D culture solution for all kinds of cell resources, including liquid biopsy, tissue, and cell line.
- Organoid development within 2 week.
- Patented technology for organoid banking services, cell production, and drug discovery.
- Best for isolating rare cell in primary culture.

### Application Areas

Precision medicine, Regenerative medicine, Drug discovery, Organoid banking, Alternative animal testing, Organ-On-Chip

### Contact Information

Name  
**Elain Lin**  
Position  
**Business Development Specialist**  
Tel  
**+886 975 260 378 (WhatsApp)**  
Email  
**elain.lin@acrocyte.com**



## Business Interests

- **Joint Drug Discovery:**  
Partnering for breakthrough research.
- **U.S. Partners Wanted:**  
Collaborating with CROs, pharma, and academia.
- **Platform/Product Development:**  
Transforming scientific breakthroughs into tangible advancements.

## Contact Information

Name  
**Kevin Chao**

Position  
**Chief Strategy Officer**

Tel  
**+886 965 743 077**

Email  
**kevin@cancerfree.io**

## CancerFree Biotech

### Main Products / Services / Pipelines & Platforms

- **Real-time Organoid System (E.V.A. Ex Vivo Avatar):**  
With just blood samples, E.V.A. creates patient-derived organoid models that mirror clinical outcomes, enhancing the precision of cancer drug development.
- **Streamlined Drug Development:**  
Accelerates biomarker discovery, optimizes therapies, and reduces trial risks, supporting the entire drug lifecycle from discovery to licensing.
- **Cost-Effective & Efficient:**  
Allows companies to quickly verify drug efficacy in tumor suppression, facilitating faster, more reliable advancements in personalized medicine.



## Business Interests

- We plan to raise series B funding in 2H 2024 to accelerate the development of our clinical assets.
- We also welcome the opportunities of out-licensing or co-development.

## Contact Information

Name  
**Chen-Hsuan Ho**

Position  
**Director of Translational Sciences**

Tel  
**+886 (2) 2782 7700 Ext.37**

Email  
**chho@elixiron.com**

## Elixiron Immunotherapeutics

### Main Products/ Pipelines

Elixiron Immunotherapeutics is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for autoimmune/neurodegenerative diseases and cancer.

#### Indemakitug (EI-001)

- A fully human anti-interferon- $\gamma$  monoclonal antibody in development for treatment of vitiligo
- Potentially first-in-class therapeutic antibody for vitiligo
- Well-tolerated in phase I trial
- On track to start a proof-of-concept clinical study in vitiligo patients in 2H 2024

#### Enrupatinib (EI-1071)

- A microglia-targeting immunotherapy for treatment of Alzheimer's disease
- Two-time winner of Part-the-Cloud awards from Alzheimer's Association
- Excellent safety profile demonstrated in phase I study
- On track to start a proof-of-concept Phase II study in Alzheimer's patients in 2H 2024

#### EI-220

- mRNA-based cancer immunotherapy
- Novel mechanism of action: to revitalize exhausted T cells by metabolic reprogramming
- Unique molecular design enabled by proprietary T-Action Technology
- Excellent antitumor efficacy revealed in mouse tumor models; plan to start IND-enabling studies in 2H 2024



www.efbiotech.com



## Everfront Biotech

### Business Interests

- Collaborative RD: US
- Out-Licensing: Other countries

### Main Products

- Cerebraca® Wafer, a survival of 26.2 months in patients with recurrent high-grade glioma
- EFs Capsule, safety profile exploration

### Contact Information

Name  
Liu, Jen-Wei Ph.D.  
Position  
Chief Scientific Officer  
Tel  
+886 958 605 379  
Email  
coldwee@efbiotech.com



www.hebiotech.com



## Health Ever Bio-Tech Co., Ltd.

### Business Interests

- Out-Licensing
- Collaborative R&D
- Urology

### Main Pipelines

New Drug Product Botreso® for BPH/LUTS.

### Contact Information

Name  
Alex Chen  
Position  
Business Development Director  
Tel  
+886 (2) 2732 5205 Ext.20  
Email  
alex.c@hebiotech.com



### Business Interests

- Seeking collaborative opportunities in high-potent active ingredient development.
- Partnering on clinical studies.
- RenoSorb™ technology technical platform service.

### Contact Information

Email  
Ingredient (US/CA) :  
mtb@pharm-rxchem.com  
Ingredient (Other country) / Technical / Investment / Others:  
clairefang@hughesbiotech.com

### Hughes Biotechnology Co., Ltd.

#### Main Products / Services / Pipelines & Platforms

##### RenoSorb™ Technology

Revolutionizing phytochemicals through a novel biosynthetic platform

##### RenoFlavone™ CB1R antagonist

- Marijuana-induced cardiovascular disease
- Next-generation genistein

##### RenoCidin™ Cisd2 activator

- Anti-aging and longevity
- Next-generation hesperetin

##### RenoVital™ CD38 inhibitor

- Age-related mitochondrial dysfunction
- Next-generation apigenin

##### RenoSage™ PPAR $\gamma$ agonist

- Alzheimer's disease and neuro-inflammation
- Next-generation luteolin



### Business Interests

Seeking out-licensing and collaborative R&D opportunities for first-in-class drugs based on innovative proprietary technology.

### Contact Information

Name  
Zoe Chen  
Position  
Project Manage/ Research Scientist  
Email  
zoe.chen@onenessbio.com.tw

### Oneness Biotech Co., Ltd.

#### Main Products

**ON101** is a topical macrophage regulator, a clinical breakthrough new drug for chronic wounds. With new drug approval in Taiwan, China, Macau, Singapore and Malaysia, and FDA's fast track designation, ON101 is a game changer in chronic wound healing and will impact millions of lives.

**FB825** is a first-in-class anti-IgE B cell monoclonal antibody for allergic diseases, such as atopic dermatitis. Its novel mechanism of targeting and inhibiting the source of IgE enables its potential in disease modification to deliver dosing advantage and better safety. FB825 has been out-licensed to LEO Pharma since 2020.

**FB704A** is a monoclonal antibody targeting the validated IL-6 pathway with best-in-class anti-inflammatory properties and well-supported safety profile. It is in Phase 2 clinical trial for severe asthma.

**SNS812** is a siRNA new drug targeting a broad-spectrum of SARS-CoV-2 variants. It can tackle any future emerging wave and flu-like existence of coronaviruses. SNS812 is under a Phase 2 clinical trial in the US and in Taiwan.



## Pythia Biotech Ltd.

### Business Interests

- Collaborative R&D

### Main Products / Services /

Pythia Biotech provides organs-on-chips which serve as an ex vivo testing system for drug development and personalized medicine.

- Tumor microenvironment (TME)-chip was proved to demonstrate the efficacy and cell-cell interaction from combination therapy of Immuno-chemo. The specialty of TME-chip was the inclusion of immune environment.
- Liver-chip demonstrated the responses from liver specific proteins to the medicine.
- Connection of these two biochips could serve as a platform to evaluate the clearance rate of the pulmonary metabolic.

Pythia Biotech is growing towards a complete pharmacokinetics system and a testing platform. This system can avoid influence from animal materials and different immune responding.

- Primary cells can be applied and reconstructed on biochips for personalized medicine.
- Besides organs-on-chips we provide services too. Please contact us to find out more.

### Contact Information

Name  
**Shih-Wen Chueh**

Position  
**Secretary**

Tel  
**+886 (2) 2653 8685 Ext.2018**

Email  
**shihwen\_chueh@pythiabiotech.com**



## Simpson Biotech Co., Ltd.

### Business Interests

- Out-Licensing
- CDMO for Recombinant Proteins
- Fermented Natural Ingredients for Dietary supplements & Cosmetics

### Main Products / Services / Pipelines & Platforms

Recombinant Protein Production: From Strain Construction to Mass Production

- Self-developed, IP-free Pichia pastoris expression vector: methanol-free and antibiotics-marker-free
- Patented platform for the expression and purification of recombinant proteins by starch-binding protein
- Variety of proteins expressed, including industrial enzymes, cytokines, and growth factors
- Already implemented for industrial enzyme production by a US-based company

Small Molecular Compound for NAFLD

- Prevent liver oil accumulation (US, CN, TW patents)
- Prevent liver-fibrosis
- Anti-inflammation, anti-oxidation
- Improve liver regeneration

ANTRODIA CINNAMOMEA EXTRACT (INCI Name), patented skin-whitening, anti-aging, anti-inflammation natural ingredients from fermented medicinal fungus

Dietary Supplement Ingredients:

- Antrodia cinnamomea mycelia for liver protection & hangover relief
- Fucoidan for metabolic syndrome & Immune booster
- StarchMate® for glycemic index reduction
- Fermented ginseng & Ginsenoside compound K for brain health
- Fermented GABA by lactobacteria using rice extract for promotes sleep, aids in relaxation

Natural Anti-Bacteria & Anti-Yeast Chitosan at 50 ppm

### Contact Information

Name  
**Chang-Chih Chen**

Position  
**Project Manager/  
Research Scientist**

Tel  
**+886 (3) 396 3466**

Email  
**bio@simpsonbiotech.com**



## Business Interests

Initiate the business discussions for STM-001, 002, 003 licensing or collaborations (product handover after receiving FDA "breakthrough" designations).

## Contact Information

Name  
**Isaac Cheng**  
 Position  
**VP Research**  
 Tel  
**+1 909 713 7187**  
 Email  
**isaac.cheng@suntecmedical.com**

## Suntec Medical, Inc.

### Main Products

Suntec is a clinical stage biopharmaceutical company with MINC (Multi-target Immune-modulation Nanocomplex) platform. MINC generates first in class NME/NCE with high efficacy and safety. Three products are ready for out-licensing/collaboration discussions.

#### STM-001

- Indications: Glioma (plus 5 other Cancers)
- Stage: Phase 1 (at M.D. Anderson, Johns Hopkins, Northwestern).
- Received NIH award as "The most promising cancer drugs"

#### STM-002

- Indications: Liver cancer (plus immunotherapy to overcome resistance to anti-PD-(L)1)
- Stage: IND ready (6/2025)
- In collaboration with Dr. T. Honjo, 2018 Nobel laureate.

#### STM-003

- Indications: Alzheimer's (plus Parkinson's, Multiple sclerosis)
- Stage: IND ready (12/2024)
- Interests from ADDF and several major pharmaceutical companies
- All three drugs expect FDA "Breakthrough Designation" with 18 yr IP protections



## Business Interests

- Out-Licensing
- Collaborative R&D

## Contact Information

Name  
**Ms. Dawn Chi**  
 Position  
**Corporate & Medical Communications**  
 Tel  
**+886 (2) 2655 7377 Ext.136**  
 Email  
**dawn@tlcbio.com**

## TLC BioSciences

### Main Products / Services / Pipelines & Platforms

TLC BioSciences is a late clinical stage specialty pharmaceutical company. At TLC, we are dedicated to the research, development, and commercialization of novel nanomedicines that maximize the potential of our proprietary lipid-assembled drug delivery platforms (LipAD®). With three approved drugs in our track record, our expertise in liposome science allows for a combination of rapid onset and extended benefit duration, enhancing active drug concentrations while minimizing systemic exposures.

Our BioSeizer® technology enables local sustained release of therapeutic agents at the site of disease or injury. Our NanoX® active drug loading technology alters systemic exposure and potentially reduces dosing frequency. Our new early-stage assets include gene therapy and lipid nanoparticle (LNP) treatments with the potential to regenerate cells.

Versatile in active pharmaceutical ingredients and scalable in manufacturing, these technologies address unmet medical needs in orthopedics and pain management.

### Pipeline

#### Orthopedics:

- TLC599 (osteoarthritis pain relief)
- TLC590 (postsurgical local analgesic)
- TLC504/503/502/501 (gene therapy)

#### Others:

- Ampholipad® (systemic fungal infections)
- TLC399 (macular edema)
- TLC178 (advanced malignancies / soft tissue sarcoma)
- TLC19 (lung diseases)



www.trust-biosonics.com



### Trust Bio-sonics Inc.

---

#### Business Interests

- Out-Licensing
- Collaborative R&D
- CDMO for Microbubble Formulation

#### Main Products / Services / Pipelines & Platforms

- Ultrasound Enhancing Agent (Microbubble/Microsphere) for Contrast Echocardiography and Diagnosis of Abdominal Lesions (in Phase 3 Clinical Studies)
- Targeted / Molecular Ultrasound Imaging Solution
- Ultrasound-Mediated Targeted Drug Delivery Platform for Enhanced Cancer Therapy

#### Contact Information

Name  
Chung Hsin Wang

Position  
General Manager

Tel  
+886 (3) 668 4965 Ext.227

Email  
chwang@trust-biosonics.com



xanthobio.com/en/



### Xantho Biotechnology Co., Ltd.

---

#### Business Interests

- Out-Licensing
- GM-XANTHO is available for out-licensing with rights in drug development and commercialization.

#### Main Products

GM-XANTHO

- Non-steroidal topical new drug for treating atopic dermatitis
- Effective in treating and preventing inflammatory skin conditions
- Currently in Phase 2a clinical study for atopic dermatitis
- Low side effects
- Available in large quantities with PIC/S GMP specification

#### Contact Information

Name  
William Wu

Position  
Head of Business Development

Tel  
+886 (2) 2655 7790

Email  
william@xanthobio.com





## Business Interests

BORA's team is here to discuss how we can become a trusted partner to help bring your breakthrough biologics successfully to market utilizing our platform & unique developer experience.

Biologics CDMO:

Establishing Cell Line, Process Optimization, Analytical/Formulation Development, Tox Study Material, cGMP Manufacturing, Global Quality, Stability Programs, Clinical Support

## Contact Information

Name  
**Steven Huang**  
Position  
**Director of Business Development**  
Tel  
**+886 (3) 658 3899**  
Email  
**steven.huang@borabiologics.com**

## Bora Biologics Co., Ltd.

### Main Products / Services / Pipelines & Platforms

BORA is the largest CDMO in Taiwan with 9 cGMP sites in Taiwan, USA, Canada and comprehensive biologics & small molecule CMC development and commercial manufacturing capabilities.

**BORA's areas of expertise specifically tailored for biologics are:**

- CMC Program Design from DNA to IND & Risk Assessments/Mitigation
- High-Titer Proprietary Cell Line Development with No Licensing Fees with GMP Batch Manufacture
- Process Development & Optimization Platform
- Analytical Method Development/Qualification/Validation, All Inclusive
- Full Formulation Development, including High Concentrations
- cGMP Manufacturing for US, EU, and Global Clinical Trials
- In-Depth Protein Characterization for Complex Molecules with 45+ Assays in-house

**BORA's experience across multiple protein classes cover:**

- Monoclonal Antibodies
- Fc Fusion Proteins
- Bi-Specific/Tri-Specific Antibodies
- Enzymes and other Recombinant Proteins
- Antibodies used in ADC construction
- Complex Protein Conjugates



## Business Interests

- Collaborative R&D
- New drug development company
- CRO

## Contact Information

Name  
**Jo Hsu**  
Position  
**Senior Project Specialist**  
Tel  
**+886 (6) 505 7128 Ext.117**  
Email  
**jo.hsu@krisanbiotech.com**

## KriSan Biotech

### Main Products / Services / Pipelines & Platforms

CDMO service / GMP manufacturing

- Lipid-based Nanocarrier (LNP)
- Complex Small Molecule
- Peptide-Drug Conjugate (PDC)
- Antibody-Drug Conjugate (ADC)



www.aheadmedicine.com



## AHEAD MEDICINE CORPORATION

### Business Interests

- Out-Licensing
- Collaborative R&D

### About

AHEAD Medicine is a pioneering healthtech company. Our flagship solution, Cyto-copilot platform, is revolutionizing flow cytometry data analysis workflow. Cyto-copilot improves the efficiency, reproducibility and scalability of services for disease diagnosis, monitoring, and ensuring quality control in cell therapy.

### Mission Statement

At AHEAD, we are committed to bridging the gap in healthcare equity and addressing the shortage of healthcare professionals through our advanced data analysis solutions. Our mission is to deliver systems that are swift, precise, consistent, and expandable. We strive to improve patient care by pioneering the development of cutting-edge healthcare technologies, propelling the industry toward a more innovative and efficient future.

### Main Products / Services / Pipelines & Platforms

Cyto-copilot is an AI-enabled data analysis platform technology that revolutionize flow cytometry analysis workflow.

Cyto-copilot provides fast, consistent, adaptable and scalable cytometry analysis for biomedical research development, disease diagnosis/monitoring, and cell therapy quality control.

### Contact Information

Name  
**Andrea Wang**  
Position  
CEO  
Tel  
**+886 919 393 398 / +1 510 389 5920**  
Email  
**andrea.wang@aheadmedicine.com**



www.bioprosscientific.io/solutions/braindee



## BioPro Scientific

### Business Interests

- Collaborative, the device can be used for patient screening in clinical trials as the preselection tool of specific group with the same pathological brain signals.
- Collaborative, the device can be used for high density EEG collection identifying patient cohort based on the brain signals.

### Main Products / Services / Pipelines & Platforms

BrainDee: Wearable Neuromodulator for Personalized Brain Health

- A wireless, non-invasive brain modulator that facilitates homeuse by telemedicine.
- Simultaneous recording and stimulation to optimize stimulation protocols and to investigate the efficacy of neuromodulation in real time.
- Non-invasive brain modulator that supports tACs, tDCs, tRNS, CES, and more.
- Integrating proprietary chips with soft, noise-proof electrodes to enable high-quality EEG recording with minimum interferences.
- AI-assisted biomarker detection for multiple CNS diseases
- Personalized design on the BrainDee cap ensures the most feasible electrode placement for each subject.

### Contact Information

Name  
**Hsin Chen**  
Position  
CEO  
Tel  
**+886 963 025 235**  
Email  
**hchen@bioproweb.com**



dotspaceinc.com



### Dotspace Inc.

#### Business Interests

- Seeking healthcare institutions with perioperative care and critical care units for clinical trial collaboration in California.
- Looking for distributors and sales representatives interested in continuous intra-abdominal pressure monitoring and renal failure prediction.
- Pharmaceutical partners interested in continuous intra-abdominal physiological data monitoring during new drug development is welcomed.

#### Main Products / Services / Pipelines & Platforms

- Digital Capsule Platform: intra-abdominal and intra-gastrointestinal pathophysiological factors monitoring.
- Renal failure prediction by intra-abdominal environment monitoring & analyzing algorithms

#### Target:

- Continuous intra-abdominal pressure monitoring for ICU and perioperative patients.
- Critical care and perioperative essential physiological data monitoring and adverse events prediction.

#### Contact Information

Name  
**Johnson Chou**

Position  
**COO**

Tel  
**+886 910 089 124**

Email  
**JohnsonChou@dotspaceinc.com**



www.ipreginc.com



### iPreg Inc.

#### Business Interests

- Distribution
- In-/Out-Licensing
- CDMO
- Collaborative R&D

#### Main Products / Services / Pipelines & Platforms

Main Product: **SperSort™**

iPreg stands at the forefront of addressing infertility challenges, particularly focusing on solutions for male infertility. Our pioneering product, SperSort™ represents a significant leap in fertility technology. By leveraging fluid dynamics and sperm motility characteristics, SperSort™ enables rapid and precise selection of healthy sperm during assisted reproductive procedures. What distinguishes SperSort™ is its ability to maintain the integrity of sperm DNA, crucial for ensuring the health of the embryo.

This groundbreaking technology not only streamlines the fertility treatment process but also significantly enhances the efficiency and success rates of in vitro fertilization (IVF) procedures. iPreg's commitment to advancing reproductive medicine underscores our dedication to improving human health and the well-being of future generations.

#### Contact Information

Name  
**Roy Lee**

Position  
**Product Manager**

Tel  
**+886 911 378 186**

Email  
**roy.lee@ipreginc.com**



## Business Interests

- Direct sales
- Authorized dealers
- Authorized agent
- Collaborative R&D

## Lixel Inc.

### Main Products / Services

Hardware LFIAT is placed horizontally, with 3D floating images standing on its surface. Users view the 3D images sideway with the naked eye, experiencing strong stereoscopic and vivid effects. The concept of light field spatial imaging reduces discomfort associated with VAC. Users can use their fingers to interact directly with 3D floating images in the air.

Software SpatiumNEX is a human-centric application based on Lixel's image and spatial computing algorithms and interactive algorithms. Its functions are divided into View in Air, Edit in Air, and Remote Connection.

Solution allows for the input of patients' MRI and CT slices into the software. It undergoes the following process: segmentation, 3D model reconstruction, transformation into 3D floating image. Users can manipulate and edit 3D floating image in air, enhancing efficiency in healthcare and medical education and evolving the value of medical image. Remote connection enables individuals from different locations to simultaneously view and edit 3D floating image, thus creating a new form of telemedicine.

## Contact Information

Name  
**Alex Yang**  
Position  
**CEO**  
Tel  
**+886 (3) 668 6628 Ext.12**  
Email  
**alex.yang@lixelinc.com**



## Business Interests

- Out-Licensing of **Mucover Intra-Oral Patch for Oral Mucositis**
- Out-Licensing of **Mucoat Oral Rinse for Oral Mucositis**
- Cooperation on **Transmucosal Drug Delivery R&D**
- Distribution Partnership **(Marketing Authorization Holder)**
- Seeking a **\$1 million investment for pivotal post-market clinical trials**

## Moculex Co., Ltd.

### Main Products / Services / Pipelines & Platforms

[Oral Mucositis Management and Transmucosal Drug Delivery System]

Oral Mucositis, a common side effect of cancer treatment, presents as severe oral ulcers, causing extreme pain and impeding life-saving cancer therapies. Moculex has secured the Taiwanese medical device license for the world's first large-area patch wound dressing for oral mucosa, utilizing the unique MuCover® mucosal adhesion technology.

MuCover® Bioadhesive Technology lies at the heart of oral wound dressings, facilitating quick and stable adhesion to moist tissues surfaces. Moculex provides MuCover® Tape, a mucoadhesive tape, and MuCoat® Glue, a bio-adhesive.

MuCover® currently serves as a Trans-Mucosal Drug Delivery system, overcoming challenges associated with oral dosage forms, such as the First-Pass Effect, offering faster and more effective drug delivery. In comparison to injectable forms, it is more convenient and safer, enabling prolonged drug release in specific local tissue areas, suitable for formulations containing amino acids, vitamins, plant extracts, and other API.

## Contact Information

Name  
**Shaun Liao**  
Position  
**CEO**  
Tel  
**+886 918 768 169**  
Email  
**SYL@moculex.com**



www.ori.bio.com.tw/en/home



### Origin Biotechnology Co., Ltd.

#### Business Interests

- Collaborative R&D
- OEM/ODM
- Product distribution
- Product Agency
- CRO

#### Main Products

- PCR-CE FMR1 Kit, mFMR1 Kit
- PCR-CE SMN1-2 Kit
- SMARt™ PS SMN1/2 Kit, SMN1/2 Advanced Kit, LR SMN1 Mutation Kit
- Male factor infertility detection kit
- Kawasaki chemotaxis kit
- PCR-CE DMD Kit
- Rapid aneuploidy detection Kit
- Pregnancy loss detection Kit
- GenoAnalyzer software
- PCR-CE NIID/ TCF4/ SCA3 Kit
- PCR-CE Alzheimer risk Kit
- PCR-CE  $\alpha$ -,  $\beta$ -Thalassemia Kit

#### Contact Information

Name  
**Willie Chen**

Position  
R&D Research Associate

Tel  
**+886 (2) 3393 1118 Ext.12**

Email  
yuwei@ori.bio.com.tw



www.qtmedical.com



### QT Medical Inc.

#### Business Interests

- Distribution
- Collaborative R&D
- Project Collaboration
- Cross-Industry Alliance

#### Main Products / Services / Pipelines & Platforms

Powering Clinical Trials Through Reliable 12-Lead ECG Solutions

##### • PCA500 RECORDER

Intuitively simple, compact, and mobile

##### • QHeart Sensor™

Single-use and pre-positioned sensor replaces 10 leadwires

##### • QT ECG APP

User-friendly, available for iOS and Android mobile devices

##### • ECG cloud

Provides preliminary interpretation

HIPAA compliant cloud management accessible from anywhere

#### Contact Information

Name  
**Shirley Wang**

Position  
VP of BD

Tel  
**+1 909 303 0007**

Email  
marketing@qtmedical.com



www.anivance.io/tw



## Anivance AI

### Business Interests

- In-/Out-Licensing
- Collaborative R&D
- CRO Partnerships
- CDMO Services
- Technology Platforms
- Analytics as a Service (AaaS)

### Main Products / Services

- **LungChip G2:** All-encompassing solutions for chip design, manufacturing, and verification for simulating personalized physiological conditions to develop disease models (e.g. COPD & CF) for research and treatment evaluation
- **LungChip MPS:** Essential for evaluating liposome, mRNA-LNP, and inhaled drug delivery systems, covering toxicology, ADME studies, and pharmacodynamics efficacy analysis.
- **LungChip AI:** AI-driven analysis involves processing and interpreting large data sets, enhancing workflow efficiency and accuracy in results.

### Contact Information

Name  
Guan-Yu Chen Ph.D.  
Position  
Professor / Founder  
Tel  
+886 (3) 573 1920  
Email  
guanyu@nycu.edu.tw



www.cytoaurora.com/en



## CytoAurora Biotechnologies

### Business Interests

- Out Licensing
- Collaborative R&D
- Instrument Sales

### Main Products / Services / Pipelines & Platforms

#### ABOUT US

CytoAurora Biotechnology integrates semiconductor and electronic engineering, AI software development, precision machinery, molecular pathology, and biochemistry, offering high-quality equipment, biochips, and comprehensive technical support.

Our primary focus lies in single-cell technology research and equipment development. This encompasses cancer cell extraction and analysis for precision medicine detection, automatic sorting, and cultivation of living cells for CDMO.

### Contact Information

Name  
Bryan Tang  
Position  
Vice President  
Tel  
+886 (3) 610 5568 Ext.8850  
Email  
bryan.tang@cytoaurora.com



jellox.com/en/home/



### JelloX Biotech Inc.

#### Business Interests

- In-/Out-Licensing
- Collaborative R&D
- Collaborative New Drug Development.

#### Main Products / Services / Pipelines & Platforms

- Startup specializing in 3D digital pathology and AI for clinical diagnoses.
- Develops 3D AI models for spatial recognition in cancers (lung, prostate, breast, head and neck, and colorectal, etc.).
- Compatible with fresh and FFPE tissues; enhances pathology workflows.
- Supports H&E, IHC, genetic tests, and a Panoramic Pathology Platform for tumor analysis.
- Coverage of Biomarker: Her2, PD-L1, Ki-67, ER, PR, panCK, TTF1, EGFR, PD-L1, CD3, CD4, CD8, CD20, CD31, CD45
- JelloX MetaLite: CPU-based edge AI, Intel Market Ready Solution.
- Partners with Roche Diagnostic and Intel for an AI+federated learning digital pathology platform.
- Closely working with Mayo clinical, National cancer center East hospital, Erasmus university, Rotterdam Medical center
- Aims to revolutionize smart hospitals and labs; seeks global partnerships for expansion.

#### Contact Information

Name  
**Servina Liu**

Position  
**CBO**

Tel  
**+1925 667 7687**

Email  
**servina.liu@jellox.com**



marker-x.com



### Marker Exploration Corporation (Marker X)

#### Business Interests

- Out Licensing: Early Cancer Detection Platform Technology Licensing.
- Collaborative R&D: Collaborating with Medical Centers, Hospitals, and Clinics to Develop Precision Cancer or Other Disease Screening Services.
- LDTs & IVD: Laboratory Services for Early Cancer Screening and Developing IVDs
- Cross-Industry Collaboration: Integrating Services with the Insurance Industry.

#### Main Products / Services

Marker X Multi-Cancer Early Detection Service.

- Marker X Utilizes high-resolution mass spectrometry to analyze protein expression and modifications, coupled with ~3000 clinical blood samples, AI machine learning, and multi-indicator algorithm, a novel and efficient cancer indicator has been developed.
- Cancer proteomic profiles for lung cancer, colorectal cancer, breast cancer, and esophageal cancer have been successfully established, with an accuracy exceeding 95% for early-stage cancer.
- With a mere 3 mL blood draw, test results can be obtained within 10 days.
- The sensitivity of the examination encompasses the earliest stages of carcinoma in situ and first-stage cancer. In comparison to other tests, cancer proteomics more accurately reflects the current physiological state, thereby reducing the risk of misdiagnosis.

#### Contact Information

Name  
**Leo Huang**

Position  
**CEO**

Tel  
**+886 960 364 146**

Email  
**leohuang@marker-x.com**



## Business Interests

- Out-Licensing
- Collaborative R&D

## Anbogen Therapeutics

---

### Main Products / Pipelines

AnBogen is a clinical-stage biotech company developing small molecule drugs to address the unmet need in cancer.

#### Pipeline:

##### ABT-101

- Best-in-class, oral, tyrosine kinase inhibitor targeting HER2 mutations in multiple solid tumor cancers.
- Superior safety, PK/PD demonstrated in phase 1
- Phase 2 study will planned in 2024

##### ABT-301

- Best-in-class, pan-HDAC inhibitor for IO combination to treat solid tumors
- Superior anti-tumor activities when combined with PD-1/PD-L1 inhibitors in pre-clinical model
- Strongly modulates tumor microenvironment
- Phase 1b trial of ABT-301/IO combo is planned in 2024

## Contact Information

Name  
**Angus Wu**  
Position  
VP, Business Development  
Tel  
**+886 (2) 8979 8616**  
Email  
**angus.wu@anbogen.com**



## Business Interests

- Collaborative R&D
- CDMO
- In-/Out-Licensing

## ImmunAdd Inc.

---

### Main Products

ImmunAdd develops innovative and practical solutions for human health. We aim to harness the immune system to create next-generation immunotherapeutics for the treatment of infectious diseases and cancer.

#### Vaccine adjuvant system- IA-05 & IAS-01

- Fully-synthetic saponin based adjuvant
- Increase cell-mediated immunity
- Enhance cross-presentation
- Well-tolerability
- Sustainable and Innovation

#### Small molecule drug conjugates(SMDC)

- Specific to cancer cells
- Lower side effects of the active drug
- Improve therapeutic efficacy
- Design an enzyme B sensitive linker to connect warhead and tumor-selective ligand

## Contact Information

Name  
**Pi-Hui Liang**  
Position  
CEO  
Tel  
**+886 (2) 3366 8695**  
Email  
**phliang@immunadd.com**





ibraintx.project.sinica.edu.tw



## Business Interests

- Out-Licensing
- Co-Development

## Neural Rejuvenation Team (NRT), Biomedical Translation Research Center (BioTReC), Academia Sinica

### Main Product

To date, the treatment of many neurodegenerative diseases, including Alzheimer's disease (AD), is still an unmet medical need.

To develop new therapeutic strategies, NRT has successfully synthesized and optimized a new chemical entity, J4, with a novel MOA and a first-in-class approach to treat AD and AD-associated sleep disorder by targeting the dysregulated nucleoside homeostasis in the brain and subsequently ameliorates neuronal energy failure. This approach also holds promise for benefiting other neurological disorders, such as Tuberous sclerosis complex (TSC).

### J4, an ENT1 inhibitor

- Orally active and BBB-permeable
- Decent bioavailability (F=65%)
- No drug-drug interaction
- Potent efficacy (Improve memory, reduce A $\beta$ /pTau load and restore sleep pattern)
- Excellent non-clinical safety
- CMC well characterized (Kilogram-scale manufacture good stability)
- Strong IP position (Major markets well protected: USA, EP, Japan, China, Australia, Korea, etc.)

## Contact Information

Name  
**Ching-Wen Wu**

Position  
**Project Manager**

Tel  
**+886 (2) 2789 9034**

Email  
**as0210292@gate.sinica.edu.tw**



www.sinewpharma.com/en/



## Business Interests

- Licensing
- Co-Development
- Strategic Alliance

## Sinew Pharma Inc.

### Main Products / Services / Pipelines & Platforms

Sinew Pharma is focused on the development of the following three assets:

- Hepatotoxicity-free acetaminophen with the pivotal study completed in which no clinically significant hepatotoxicity was observed among the cohorts of study participants taking 4 to 12 grams per day.
- A novel analgesic combination with non-hepatotoxic acetaminophen and a non-addictive & no/mild respiratory depression kappa-opioid for severe pain management: (1) The pivotal study has completed enrollment of patients undergoing knee replacement; (2) It is a safer and more effective alternative to traditional  $\mu$ -opioids to combat opioid crisis.
- First-in-class NCE with high safety profile for MASH (Metabolic dysfunction-associated steatohepatitis) treatment; tackling multiple pathways impacting its pathogenesis with Phase 2a clinical study completed.

## Contact Information

Name  
**Chu-Chun (June) Huang**

Position  
**Director of Business Development**

Tel  
**+886 (2) 2788 5365 Ext.531**

Email  
**cchuang@sinewpharma.com**



## TAHO Pharmaceuticals Ltd.

### Business Interests

Seeking out-licensing, CDMO opportunities for novel drug delivery systems

### Main Pipelines

- TAH4411 – Antiemetic – Ondansetron OD Film
- TAH3311 – Anti-Thrombotic – Apixaban Oral Dissolving Film
- TAH3341 – Anti-Thrombotic – Apixaban Oral Extend Release Film
- TAH2211 – Opioid Addiction – Buprenorphine / Naloxone Sublingual Film
- TAH2231 – Opioid Overdose – Naloxone Buccal Film
- TAH9901 – ADHD – Methylphenidate Transdermal Patch
- TAH9922 – ADHD – Atomoxetine Oral Liquid

### Contact Information

Name  
Milky Kao  
Position  
BD VP  
Email  
milkykao@tahopharma.com



## FaceHeart Corporation

### Business Interests

FaceHeart provides a cross-platform Software Development Kit (SDK) or Web page for any players who are interested in adopting contactless vital sign measurements as part of their service offerings.

- Hardware Vendors (IDH/ODM/OEM)
- Medical Channels
- Value-added Service Providers
- Smart Health Application/Management
- SmartHealth Service Solution/Platform

### Contact Information

Name  
Marketing Team  
Tel  
+886 (2) 8978 1888 Ext.168  
Email  
marketing@faceheart.com

### Main Products / Services / Pipelines & Platforms

FaceHeart Corp. improves human health through its FDA 510 (k) cleared AI-driven, video-based contactless vital signs solution, FaceHeart Vitals™, providing a simple, comfortable, and cost-effective method to help patients manage their health.

### Main Products

With only a single camera, our cutting-edge technology measures the following vital signs: Heart Rate (HR), Blood Pressure (BP), Respiration Rate (RR), Oxygen Saturation (SpO2), Heart Rate Variability (HRV), Atrial Fibrillation (AFib), and Stress Index.

Facilitating seamless integration, FaceHeart offers software development kits (SDK) compatible with various devices and online services. In addition to transferable data formats, FaceHeart Vitals™ SDK supports multiple operating systems including iOS, Android, Windows, and Linux, enabling adaptable measurements across smartphones, tablets, computers, smart home devices, and embedded boards.

### Key features

- 150M Images from >5000 Patients
- FDA 510(k) NO: K223622
- Medical-Grade Accuracy
- Supports Web & Edge Solutions



## Neurobit Technologies

### Business Interests

- SalesPartners
- Dealers
- Distributors
- Hardware Vendors (Not limited to Eye Tracking Hardware)
- Digital Health Solution Providers

### Main Products / Services / Pipelines & Platforms

We introduce NeuroSwift as the cornerstone of our swift and user-friendly neurological diagnostic tools, enriched by cutting-edge eye tracking technology. NeuroSwift AIVertigo encompasses a suite of video nystagmography techniques, multimodal algorithmic models, and user interfaces meticulously crafted for vestibular testing and neuropathy analysis in patient diagnosis. Furthermore, we are pleased to present eyeForm, an application harnessing a myopia prediction model.

In conjunction with clinical usage and user studies, we assess the prerequisites and performance benchmarks for a variety of AI models developed for our medical applications. These models encompass rule-based algorithms to intricate deep learning architectures, each equipped with specific evaluation criteria aligned with its intended use case. Our comprehensive testing includes internal and external benchmarks covering user satisfaction and clinical evaluations across trials conducted in ophthalmology, neurology, and emergency medicine.

### Main Products

- NeuroSwift Pro+ & AIVertigo: Risk Analysis and Medical Triage in patients with vertigo or dizziness
- NeuroSwift Pro : Assessment of Vestibular Function
- NeuroSwift : Dizziness/Vertigo Screening and Strabismus Detection
- eyeForm : Myopia Management Prediction and Risk Analysis

### Key Features

- FDA Clearance, CE Marking and TFDA Clearance
- Data Integration and Analysis
- Interactivity and Ease of Use
- Integration and Scalability
- Security and Privacy Protection

### Contact Information

Name  
**Chun-Chen Yang**

Position  
**CEO**

Tel  
**+886 (2) 2771 0618**

Email  
**travisyang@neurobittech.com**



## Agricultural Technology Research Institute

### Business Interests

Collaborative R&D. We offer animal study can evaluate efficacy, toxicity study using pig model and bio-safety service to biotechnology companies.

### Main Services

- **Animal Study**  
Certification: OECD-GLP and AAALAC  
Efficacy: Acute myocardial ischemia (AMI), Wound healing, Dental defect, Pulmonary fibrosis study, and Customized animal models  
Safety testing: Skin toxicity testing, Medical devices biocompatibility
- **Biosafety Testing Services**  
Certification: OECD-GLP, TFDA-GLP, and PIC/S GMP  
Service: Biological Safety Testing and Virus Validation
- **SPF Pig Tissue Supply**  
Tissues: SPF pig skin and bone  
Certification: ISO 13485:2016 according to ISO 22442-1:2015 and ISO 22442-2:2015  
Application: Production of collagen and bone meal
- **Animal Vaccine Safety and Efficacy Test**  
Swine challenge model: PRRSV, PCV2, CSF, APP, *Mycoplasma hyopneumoniae*, *Mycoplasma hyorhinis*.  
Poultry challenge model: ND (Newcastle disease), MD (Marek's disease), *Mycoplasma gallisepticum*, *Mycoplasma synoviae*.  
Others: Customized animal challenge model
- **Antimicrobial Susceptibility Test**  
Certification: ISO/IEC 17025

### Contact Information

Name  
**Ching-I Chen**

Position  
**Researcher**

Tel  
**+886 (37) 58 5857**

Email  
**1052073@mail.atri.org.tw**



nbrp.sinica.edu.tw



## Business Interests

- Collaborating with international bio-cluster/ bio-park, accelerator, incubation center, global pharma government agency, biotech association, venture capital
- Space for startup related new drug discovery, smart healthcare & precision medicine
- Translational medical research cooperation
- Core facility support

## Contact Information

Name  
Rong-Jie (Jacky) Chen  
Position  
Project Manager  
Tel  
+886 (2) 7750 5315  
Email  
cet252@gate.sinica.edu.tw

## Biomedical Translation Research Center (BioTReC), Academia Sinica

### Main Services

#### Construct a Strong Biotech Ecosystem

Forge a professional and innovative ecosystem that facilitates new drug discovery, as the creation of a thriving biotechnology industry will ultimately enhance health and welfare of society.

#### Incubate Startup Companies


Incubate companies to push the development of Biologics, Nucleic Acid Drugs & Regenerative Medicine, Smart Healthcare & Precision Medicine, and Botanical Drugs & Small Molecule Drugs. Provide one-stop service to support resident companies during R&D stage and subsequent product commercialization. Cultivate business talents by constructing training programs on scientific innovation and entrepreneurship.

#### Support Innovative Biomedical Translation Research

Solicit the most promising proposals of projects that seek to translate biomedical technologies. Facilitate industry-oriented innovation and multi-disciplinary collaboration in translational medicine, enhancing the competitiveness of new drug development and medical applications from translational research to clinical use.

#### World-Class Core Facilities

Accelerate the timeline for translational research and pre-clinical verification of innovative precision by providing researchers with advanced instruments, high-priced equipment, and technical services on disease prevention, detection, diagnosis and treatment.



www.ctsp.gov.tw/english/00home/home.aspx?v=20



## Business Interests

- Collaborative R&D
- CDMO

## Contact Information

Name  
I-Jou Chen (Athena)  
Position  
Translator  
Tel  
+886 (4) 2565 8588 Ext.1112  
Email  
ijouchen@ctsp.gov.tw

## Central Taiwan Science Park

### Main Products / Services

#### Products

- Medical & Assistive devices
- Vaccines & Drugs
- Dietary supplements
- Advanced agricultural products

#### Service

- Integrated industrial, academic and medical resources
- Developing new solutions that better support public needs



## Business Interests

Seeking in-/out-licensing, collaborative R&D, CDMO opportunities for Taiwanese biotechnology and medicine companies.

## China Productivity Center

### Main Products / Services / Pipelines & Platforms

China Productivity Center (CPC), as the executive organizer of the 2024 Taipei City Biotechnology Industry Guidance Program. We are honored to have this opportunity to gather around outstanding biotech and medical companies for Taipei City Government to participate in the world's largest event for the biotechnology industry. By showcasing their latest products and R&D activities at the event, it is our mutual goal to elevate the visibility and discover new opportunities.

#### Our core business scope:

- Management Consulting
- Government Projects
- Education and Training
- Media Publication
- International Exchange
- Management Knowledge Center

## Contact Information

Name  
**Sherry Shang**  
Position  
**Manager**  
Tel  
**+886 (2) 2698 2989 Ext.01954**  
Email  
**01954@cpc.org.tw**



## Business Interests

- Innovation and Entrepreneurship
- Academia-Industry Collaboration
- Startups
- Talent Cultivation

## Department of Academia-Industry Collaboration and Science Park Affairs National Science and Technology Council

### Main Services

**To enhance innovation and entrepreneurship for academic research**

With the innovation and entrepreneurship programs, the department encourages a deep technology from university to new venture, builds a platform like Taiwan Tech Arena (TTA) to drive more corporate with international investors and offers programs for startups to global exhibitions and talent exchanges.

#### To support academia-industry relationship

With the Academia-industry collaboration programs, the department encourages businesses to participate in university-based applied research projects, promotes collaboration on highly innovative research projects, establishes rules for co-ownership of research results, and creates alternative models for technology transfer authorization, thus increasing the effectiveness of industry-academia cooperation.

#### To cultivate industrial talents

To train S&T talents for high-tech industries, the department provides Ph.D. students with training programs both in the universities and internships for professionals.

#### To develop of science parks

The science parks strive for innovation, inclusion, and sustainability. We aim to strengthen the development policies of the science parks, review and revise related regulations, science parks enterprise investment review, talents cultivation and management integration.

## Contact Information

Name  
**Yen-Fen, Fan**  
Position  
**Executive Officer**  
Tel  
**+886 (2) 2737 7686**  
Email  
**yanfen@nstc.gov.tw**



## Development Center for Biotechnology

### Business Interests

- Out-Licensing
- Collaborative R&D

### Main Pipelines / Platforms

DCB is dedicated to advancing Taiwan's biotechnology industry through focused efforts in the research and development (R&D) of preclinical development and translational medicine research for novel drugs and treatments. Additionally, the organization is actively involved in drug commercialization and business development.

DCB's Current Pipeline

#### Biologics

- Immuno-oncology  
Preclinical  
CD73 mAb (DCBPR2201) / NSCLC  
Globo H CAR-T / Gastric Cancer  
Validation and Optimization  
PD-L1 mAb  
Tim-3 mAb  
CSF-1R mAb

- Oncology  
IND  
Raf Inhibitor / Melanoma  
Preclinical  
NTSR1 ADC (DCBAD2301) / Head and Neck Cancer  
B7-H3 ADC (DCBAD2303) / B7-H3-positive Tumors

#### Pharmaceutics

- Oncology  
Preclinical  
FPR1 Inhibitor / Neutrophil Related Inflammatory Disease

#### Platforms

- Development of Protein-degrader Drugs Against Cancer
- mRNA-LNP Production Platform
- Full Human Synthetic Library for Antibody Drug Discovery

### Contact Information

Name  
**Ching-Hsu Yang**  
Position  
**Project Manager**  
Tel  
**+886 (2) 7700 3800 Ext.5293**  
Email  
**ch.yang@dcb.org.tw**

### Business Interests

- Providing top-tier infrastructure and comprehensive one-stop services.
- Promoting industry-academia R&D collaboration. Creating a cluster of innovative ventures in world arena.
- Creating a cluster of innovative ventures in world arena.

### Contact Information

Name  
**Yuki Chen**  
Position  
**Officer, Business Promotion Section, Investment Division**  
Tel  
**+886 (3) 577 3311 Ext.2228**  
Email  
**yukichen23@sipa.gov.tw**

## Hsinchu Science Park Bureau, National Science and Technology Council

### Main Services

- Complete IC industry cluster  
Global top IC industry supply chain in upstream, midstream, and downstream offering cross-domain industry solutions in diversified high-tech sectors, e.g. big data, IoT, AI, biotech, etc.
- Brilliant platform for biomedical industries  
Development of cutting-edge medical devices and new drugs, integrating with core research facilities and hospitals, solidifying precision medical treatment industries.
- Cradle for new ventures  
Fostering a great environment for innovative ventures and entrepreneurship via terrific mentoring services and supports from surrounding academia, industries, and R&D facilities, together with close ties with global peers.
- Top ranking academia and R&D organizations with humanity concerns  
Surrounded with top leading academia and research organizations, providing fruitful talent and research resources.
- Superior service quality and efficiency via one-stop services
- The Hsinchu Science Park Bureau offers diversified one-stop services, e.g. company registration, talent cultivation, R&D grants application, factory and land leasing, etc.



## Industrial Development Administration, Ministry of Economic Affairs

### Main Mission

- The administration is in charge of the national industrial development tasks.
- Offer a full range of services according to industrial needs.
- Lead the industry of Taiwan to pursue innovation, upgrading, and enterprise transformation.
- Guide enterprises to strengthen their management system, increase productivity and enhance international competitiveness.
- Assist enterprises to face changes in the overall environment and provide policy subsidies.

### Contact Information

Tel  
+886 (2) 2655 8135  
Email  
[services@biopharm.org.tw](mailto:services@biopharm.org.tw)



## Industrial Technology Research Institute

### Main Products / Services / Pipelines & Platforms

- R&D Collaboration
- CDMO/CRO
- Out-Licensing
- GXP Trial Production

- Eye Drops Platform for Posterior Eye Delivery - Coordinated Supramolecular Complex (CSC) Technology
- ITRI-LNP Platform - Lipid-Nanoparticles for RNA-based *In-Vivo Applications* or *Ex-Vivo* Immune Cell Modifications
- Dual Phase Hydrogel - A Highly Effective Drug Delivery System with Bioactive Molecules
- One-Stop Biomedical Service:
  1. R&D Prototyping
  2. GXP Trial Production
  3. Pre-Clinical/Clinical Trial
  4. Licensing
  5. ISO Application
  6. Regulation Consulting
  7. Supply Chain of Key Material & Component
  8. Medical Device Verification
  9. Medical Device Export

### Contact Information

Email  
[ITRI\\_BDL@itri.org.tw](mailto:ITRI_BDL@itri.org.tw)



## Business Interests

CDMO, Co-development, Tech-transfer of pharmaceutical products, medical devices, botanical products and stem cell therapy products.

## Medical and Pharmaceutical Industry Technology and Development Center

### Main Products / Services

- Pharma 4.0-Continuous manufacturing
- Insoluble drug technique
  - Hot-melt extrusion drug manufacturing technology
  - Spray-dried technology
  - Nanocrystal
  - Solvent evaporation
- Long-acting injectables
  - Hot-melt extrusion-implant
  - Nanocrystal
  - Type 4/7 dissolution apparatus
- Lipid nanoparticle (LNP)
  - Microfluid
  - Nanosizer
  - GalNAc-Hepatocyte targeting
- Drug eluting medical devices
- Botanical product development (Small molecule drugs, Functional food)
- Stem cell pipeline for fibrosis
- Cell culture medium optimization

## Contact Information

Name  
Strategic Planning Division  
Tel  
+886 (2) 6625 1166  
Email  
pitdc\_p@pitdc.org.tw



## Business Interests

- Providing top-tier infrastructure and comprehensive one-stop services.
- Promoting industry-academia R&D collaboration.
- Creating a cluster of innovative ventures in world arena.

## Ministry of Agriculture

### Main Services

The Ministry of Agriculture is in charge of administration of agricultural, forestry, fisheries, and animal husbandry matters in Taiwan. Under the Ministry there are the Department of Planning, Department of Resources Sustainability, Department of Farmers' Guidance, Department of Animal Industry, Department of Animal Welfare, Department of Agricultural Science and Technology, Department of International Affairs, Department of Information Technology, Secretariat, Department of Personnel, Department of Government Ethics, Department of Accounting, Department of Statistics, and Department of Legal Affairs. Each department is divided into sections to meet operational needs.

## Contact Information

Name  
Meng-Fang Hsu / Hsin-Chuan Huang  
Position  
Specialist / Associate Researcher  
Tel  
+886 (2) 2312 4058 / +886 (2) 2312 4018  
Email  
mengfang@moa.gov.tw  
hsinchuanh@moa.gov.tw





[www.mohw.gov.tw/mp-2.html](http://www.mohw.gov.tw/mp-2.html)



## Ministry of Health and Welfare

### Business Interests

The MOHW's diversified responsibilities include health policy planning and promotion, prevention and control of disease, food safety, drug management, social insurance and welfare, relief and protective services.

### Main Products / Services / Pipelines & Platforms

The Ministry of Health and Welfare of the Republic of China (MOHW) is the Executive Yuan ministry responsible and the highest authority for the administration of the public health system, social welfare, affordable and universal health care, hospitals, pharmaceutical, immunization programs, disease prevention, supervision and coordination of local health agencies in Taiwan. The MOHW was originally established on 17 March 1971 as the Department of Health (DOH). The department was upgraded to Ministry of Health and Welfare on 23 July 2013 with the addition from the agencies in the Ministry of the Interior responsible for social welfare following restructuring of the Executive Yuan. The mission of MOHW is to promote the health and well-being of all Taiwan citizens.

### Contact Information

Name  
Hsien-Yang Lee  
Position  
Researcher, Office of Science and Technology  
Tel  
+886 (2) 8590 7567  
Email  
schsien-yanglee0641@mohw.gov.tw



[www.nhri.edu.tw/eng/](http://www.nhri.edu.tw/eng/)



## National Health Research Institutes

### Business Interests

- R&D Collaboration
- Licensing

### Main Services

- Advance biomedical sciences
- Promote population and individual health
- Forge biotechnology and pharmaceutical development
- Train and cultivate biomedical researchers

### Contact Information

Name  
Hua-Hsuan Liang  
Position  
Acting Section Chief  
Tel  
+886 (37) 206 166 Ext.33206  
Email  
huahsuan@nhri.edu.tw



www.nstc.gov.tw  
biomed-tw.org/



## National Science and Technology Council

### Business Interests

- IP/Tech feasibility and analysis for pharmaceuticals and medical devices
- Prototyping service for pharmaceuticals and medical devices
- Marketing analysis and regulatory compliance support for pharmaceuticals and medical devices
- Accelerate commercialization for pharmaceuticals and medical devices

### Main Products / Services / Pipelines & Platforms

The BioMed Commercialization Center (BMCC) funded by the National Science and Technology Council (NSTC), is to provide an integrated platform to overcome the bottleneck found in the development and commercialization of pharmaceuticals and medical devices for academia and industries.

### Contact Information

Name  
BioMed Commercialization Center

Tel  
+886 (2) 2652 2677 (Pharmaceuticals)  
+886 (3) 658 8760 Ext.2048 (Medical Device)

Email  
dcc@biip-dcc.org (Pharmaceuticals)  
bmcc@biip-mdcc.org (Medical Device)



www.stsp.gov.tw/web/  
indexGroups?frontTarget=ENGLISH



## Southern Taiwan Science Park Bureau, National Science and Technology Council

### Business Interests

- Collaborative R&D
- CDMO

### Main Products / Services / Pipelines & Platforms

- Pharmaceutical Products
- Dental Products Combining the Integration of Software and Hardware
- Artificial Joints, Trauma, Spine and Other Orthopedic Products
- Minimally Invasive Medical Devices
- In Vitro Diagnostic Products
- Biomedical-Grade Collagen, Wound Care Dressings, Nano Dressings, Skin External Applications and Functional Cosmeceutical Products
- Biomedical Image Detection and Intelligent Image Monitoring

### Contact Information

Name  
Hsu-Ting, Tseng

Position  
Senior Secretary

Tel  
+886 (6) 505 1001 Ext.2329

Email  
sttseng@stsp.gov.tw



## Startup Island TAIWAN

### Business Interests

Startup Island TAIWAN demonstrates the strong ambition and capabilities of Taiwan tech startups as well as their intention and ability to contribute to other startup ecosystems around the world. We hope to be your gateway to Taiwan's startup ecosystem.

### Contact Information

Name  
**Allen John Ku**  
Position  
**Director**  
Tel  
**+886 (2) 3343 5456 Ext.805**  
Email  
**allenjohn@startupislandtaiwan.info**

### Main Products / Services / Pipelines & Platforms

Startup Island TAIWAN is the national startup brand of Taiwan. Our endeavors span across various regions worldwide, with some notable programs and partnerships highlighted below:

- The Taiwan-Berkeley Health Innovation Accelerator Program is a collaboration between Berkeley Public Health, the National Development Council of Taiwan, and Startup Island TAIWAN. This initiative supports an annual cohort of Taiwanese startups aiming to introduce their health innovations to the U.S. market, providing them with access to the vibrant healthcare opportunities in the Bay Area.
- We actively facilitate Taiwanese startups in exploring SEA markets, participating in conferences in Thailand, Singapore, and Vietnam. The overarching goal is to encourage Taiwanese startups to enter SEA markets and foster bilateral business collaborations between Taiwan and the SEA region.
- We've played a crucial role in assisting our startups in navigating the Japanese markets. For one, we organize the "Together, Go Big. Japan-Taiwan Startup Summit". It represents the largest innovation conference event between Japan and Taiwan in recent years. It provides a platform for knowledge exchange with key Japanese enterprises, highlighting the potential collaboration between Japan and Taiwan in fostering Japan's economic development and digital transformation.



## Taipei City Government

### Business Interests

Welcome Int'l bio companies to land in Taipei.

### Contact Information

Name  
**Sonia Hsu**  
Position  
**Researcher**  
Tel  
**+886 (2) 2720 8889 Ext.2090**  
Email  
**ea-40177@gov.taipei**

### Main Services

- One-Stop Service
- Financial Support : Subsidies and Incentives for Taipei Industry project, Loan services, Taipei Biotech Awards...etc.
- Match Making : Bio@Taipei website, Taipei Bio Club, to disseminate industry news, promote policy resources, and cluster biotech companies and associations
- Global Linkage : Lead Taipei enterprises to participate in international biotech exhibitions
- Promote Bio-cluster : Taipei Bioinnovation Park, Beitou Shilin Technology Park



[www.tpex.org.tw/web/index.php?l=en-us](http://www.tpex.org.tw/web/index.php?l=en-us)



### Business Interests

TPEX aims to attract issuers to list securities, and provides a platform for trading of stocks, bonds, and other financial products.

### Taipei Exchange

#### Main Products / Services / Pipelines & Platforms

- Established in 1994, Taipei Exchange (TPEX) is a full-fledged exchange with dual-core business, driven by stock and bond markets. It has been a full member of World Federation of Exchanges (WFE) since 2011.
- TPEX has established a three-tiered market structure designed for companies with different sizes and development stages. "Go Incubation Board for Startup and Acceleration Firms (GISA)" provides fund-raising and counselling for micro-sized companies. "Emerging Stock Board (ESB)" is a preliminary market before IPO. "Main Board" is a market for scaled companies.
- TPEX has been recognized with remarkable market performances, such as a robust level of liquidity that enhances the investment efficiency and the reasonable P/E ratio that helps investors to assess the corporate value.
- With the aim to support SMEs, TPEX has helped over 2,400 companies enter the capital market for further expansion and continuous growth. Among them, electronics and biotechnology are two major industries.

### Contact Information

Name  
Yi Ting Chen  
Position  
Manager,  
Listing Examination Department  
Tel  
+886 (2) 2366 5926  
Email  
Sara@tpex.org.tw



[taiwanbio.org.tw/en/](http://taiwanbio.org.tw/en/)



### Business Interests

BIO Asia-Taiwan International Conference and Exhibition

### Taiwan Bio Industry Organization

#### Main Products / Services / Pipelines & Platforms

- Promoting the interests of our members
- Promoting international exchange and cooperation
- Promoting communication between government and industry
- Cultivating biotechnology industry talent
- Encouraging outstanding performance and innovation

### Contact Information

Name  
Mia Tsai  
Position  
Marketing Assistant Manager  
Tel  
+886 983 213 775 / +1 805 638 8243  
Email  
mia@taiwanbio.org.tw



## Taiwan External Trade Development Council (TAITRA)

### Company Description

Founded in 1970, TAITRA is Taiwan's foremost nonprofit trade promoting organization. Sponsored by the government and industry organizations, TAITRA assists enterprises to expand their global reach. Headquartered in Taipei, TAITRA has a team of 1,300 specialists and operates 5 local offices in Taoyuan, Hsinchu, Taichung, Tainan and Kaohsiung as well as 60+ branches worldwide. Together with Taipei World Trade Center (TWTC) and Taiwan Trade Center (TTC), TAITRA has formed a global network dedicated to promoting world trade.

### Main Services

To assist Taiwanese businesses in developing international market.

To collaborate closely with Taiwanese government in trade policy implementation.

To provide business consultation service and connect international firms with Taiwanese partners.

To assume the role of "Smart Integrator" - complement government policies, facilitate industry needs and develop new business opportunities around the world.

### Contact Information

Tel  
+886 (2) 2725 5200  
Email  
[taitra@taitra.org.tw](mailto:taitra@taitra.org.tw)



## Taiwan Stock Exchange

### Company Description

The Taiwan Stock Exchange (the "TWSE") started operations on February 9, 1962. The TWSE is not only responsible for operating and advancing the domestic securities market, but also provides comprehensive services to the stock market.

The "TWSE" is dedicated to assisting companies to list on the capital market, raising funds and expanding their operational scale. In 2021, the "TWSE" has launched a new trading platform "Taiwan Innovation Board ("TIB)," to make it easier for innovative enterprises to raise funds in capital market. The "TWSE" is looking forward to more applications from innovative enterprises from Taiwan and abroad.

### Main Services

Listing: listing promotion and review, post-listing supervision and corporate governance

Trading: maintaining market trading and order, securities firms' services, investor protection,


Settlement and Surveillance: clearing and settlement operations, safeguarding against market defaults and the monitoring of illegal transactions.

### Contact Information

Name  
Nai-Yu Kuo  
Position  
Associate, Foreign Listing Department  
Tel  
+886 (2) 8101 3627  
Email  
[1210@twse.com.tw](mailto:1210@twse.com.tw)


-MEMO-

-MEMO-



-MEMO-

-MEMO-



-MEMO-

